EAU Annual Congress



Botulinum Toxin Eases LUTS in Men

March 22, 2011

VIENNA—Botulinum toxin type A (BTA) injected into the prostate may be a safe and effective treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), according to preliminary study results presented here at the 26th Annual Congress of the European Association of Urology.
 

Novel Cause of BPH, PCa Proposed

March 22, 2011

VIENNA—Benign prostatic hyperplasia (BPH) and prostate cancer could be the result a previously unrecognized route of free testosterone flow from the testes to the prostate, according to investigators.
 

Real-Time Elastography Superior for Identifying Prostate Cancer

March 22, 2011

VIENNA—Real-time elastography has significantly better predictive accuracy for identifying prostate cancer (PCa) lesions compared with contrast-enhanced magnetic resonance imaging (MRI), researchers reported here at the 26th Annual Congress of the European Association of Urology. Biopsy studies need to confirm these results, however.
 

BoNT-A Efficacy for Idiopathic Detrusor Overactivity Confirmed

March 21, 2011

VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
 

Five-Year RARP Outcomes 'Highly Satisfactory'

March 21, 2011

VIENNA—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers "highly satisfactory" five-year oncologic outcomes, according to investigators.
 

Drug May Be an Alternative to Cystectomy for BCG Failures

March 21, 2011

VIENNA—Mycobacterial cell wall DNA complex (MCC) may provide an alternative to cystectomy for patients with non-muscle invasive bladder cancer refractory to bacillus Calmette-Guérin (BCG) treatment, according to preliminary study findings.
 

Testosterone Safe for Prostates

March 20, 2011

VIENNA—Testosterone replacement therapy benefits hypogonadal men without adversely affecting prostate safety, according to the largest international trial of hypogonadal men receiving the treatment.
 

Tadalafil Helps Men with Both ED and BPH-LUTS

March 20, 2011

VIENNA—Tadalafil can improve erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men who suffer from both problems, data suggest.
 

High-Grade PCa Linked to Metabolic Syndrome

March 20, 2011

VIENNA—Metabolic syndrome is associated with an increased risk of high-grade prostate cancer (PCa) among men with a positive prostate biopsy, a study found.
 

CKD Develops in Many Living Kidney Donors

March 19, 2011

VIENNA—One year after undergoing living donor nephrectomy (LDN), more than half of donors will have chronic kidney disease (CKD), according to a British study. Their decline in renal function, however, appears to remain stable for at least five years and patients rarely suffer adverse cardiovascular events and cardiac mortality.
 

Your Practice


Since its inception, health care providers have struggled with the need to protect patient privacy, share information, and keep paper work under control.

Read more on
Complying with HIPAA


Have any practice management topics that you'd like us to cover?
Let us know.

Legal Issues


Legal Issues

A primary care doctor referred a patient with an elevated PSA to a urologist. After a negative prostate biopsy, the doctor did not regularly conduct follow-up PSA testing, and the patient eventually died from prostate cancer.

Your Money


Your Practice

Consumer stocks do not lead the markets every year. During bull markets, investors often ignore consumer goods, which may seem dull compared to technology or finance. But over the long haul, consumer stocks tend to deliver competitive results.

Read more on
Conservative Investors, Consumer Companies in a Sluggish Economy


Newsletters

Sign up to start receiving free e-newsletters from Renal & Urology News, including:

  • Latest CME
  • Ongoing Clinical Trials
  • Conference Highlights
  • Expert Q&A
  • Weekly Round-Up

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions